Proteolysis Targeting Chimera (PROTAC) drugs have evolved from a promising concept to a clinically validated modality. In May 2026, the U.S. FDA approved vepdegestrant (Veppanu®), the first PROTAC drug, marking an important milestone for targeted protein degradation and reinforcing the approach across a multitude of disease areas. PROTACs usually consist of three parts: a target-binding…
